Our Take
This is a procedural win dressed as policy—the GAO found process failure, not proof that the AI itself is broken, and Congressional Review Act votes almost never survive both chambers.
Why it matters
Medicare AI decisions affect millions of seniors immediately. The payment structure for vendors (undisclosed formula tied to denial rates) creates a structural incentive to reject claims, and CMS has only promised audits, not structural reform.
Do this week
Healthcare AI vendors: document your approval rationale for every denial decision now, before any CMS audit begins, so you can defend accuracy if vendors with high inaccuracy rates get terminated.
Democrats introduce resolutions to overturn WISeR
Senate and House Democrats introduced concurrent resolutions Wednesday to invoke the Congressional Review Act against WISeR (Wasteful and Inappropriate Service Reduction), a Medicare pilot that uses AI to approve or deny care. Twenty Senate Democrats, led by Ron Wyden (D-Ore.), backed the Senate resolution. House members Suzan DelBene (D-Wash.) and Greg Landsman (D-Ohio) introduced the companion House version.
The Government Accountability Office ruled last week that WISeR should have been submitted to Congress for approval before implementation in January. The program is currently active in six states: Arizona, New Jersey, Oklahoma, Ohio, Texas, and Washington.
WISeR requires providers to submit certain supplies, procedures, and inpatient services to contractors that use AI to decide whether to approve or deny coverage. CMS targets procedures and supplies associated with fraud, while excluding emergency services and those that would pose substantial risk if delayed. The contractors are paid according to an undisclosed formula that includes their denial rate, a structure that outside experts warn incentivizes rejecting claims.
Vendor incentives and delayed care
In April, Senator Maria Cantwell (D-Wash.) reported that seniors in Washington faced care delays due to the program. At a congressional hearing, she characterized CMS's use of AI as a "denial device."
DelBene raised the payment structure directly with CMS administrator Mehmet Oz in recent correspondence. Oz responded that CMS will audit vendors to ensure decisions align with existing Medicare coverage criteria and will terminate vendors with high inaccuracy rates. He did not address the underlying incentive structure or disclose the formula itself.
The coalition opposing WISeR broadened beyond the six pilot states, suggesting concerns about scale. DelBene previously warned that if WISeR expands to traditional Medicare nationwide, it would replicate the prior authorization scheme already embedded in Medicare Advantage, effectively creating a "back door to privatizing Medicare."
The procedural path and realistic odds
Congressional Review Act votes are rarely successful. More than 250 rules have been challenged this way; only a handful were overturned, mostly during the transition from the Obama to Trump administrations. The resolution needs 30 Senate signatures to advance to a floor vote and a simple majority in both chambers to pass.
The resolution does not yet show bipartisan support. If it passes both chambers, WISeR would become immediately ineffective.
For healthcare systems and AI vendors working with Medicare, the immediate risk is not legislative death but operational uncertainty. Audits are coming. CMS has signaled willingness to terminate vendors with documented accuracy problems, but the threshold and methodology remain undefined. The undisclosed payment formula also means vendors cannot optimize decision-making without CMS transparency on how denials affect their compensation.